Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q1 2021 · 10-Q
Revenue$410.00K$410.00K+279.6% vs Q1 2020 Net Income-$7.53M-$7.53MN/M vs Q1 2020 EPS Diluted-$0.05-$0.05N/M vs Q1 2020 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Operating Cash Flow-$7,070,000N/M Free Cash Flowderived-$7,489,000N/M Margins · derivedGross margin73.9%
Operating margin-1688.8%+1880.7 pt vs Q1 2020
Net margin-1837.3%+2295.1 pt vs Q1 2020
ended Sep 30, 2020 · filed Nov 16, 2020 · 47 d after period end